New Drug Effective Against Pancreatic Cancer

Wednesday, 21 Aug 2013 12:15 PM

 

Share:
  Comment  |
   Contact Us  |
  Print  
|  A   A  
  Copy Shortlink

Incyte Corp said a mid-stage trial of its experimental cancer treatment showed the drug, Jakafi, improved the survival rate of patients most likely to benefit from the treatment.
The company's shares rose 20 percent in premarket trade.
The six month survival rate of patients treated with Jakafi along with chemotherapy was 42 percent, compared with an 11 percent survival rate for those on placebo.
The drug, generically known as ruxolitinib, was tested in combination with chemotherapy drug, capecitabine, to improve the overall survival of patients with advanced pancreatic cancer, as compared to capecitabine alone.
The combination of Jakafi and capecitabine was generally well tolerated in the study.
Among the patients receiving the combination therapy, 12 percent discontinued treatment for an adverse event, compared with 20 percent patients who received capecitabine alone.
Incyte shares were up 20 percent to $32.50 in trading before the bell. They closed at $27 on Tuesday on the Nasdaq.
 

© 2014 Thomson/Reuters. All rights reserved.

Share:
  Comment  |
   Contact Us  |
  Print  
  Copy Shortlink
Around the Web
Join the Newsmax Community
Please review Community Guidelines before posting a comment.
>> Register to share your comments with the community.
>> Login if you are already a member.
blog comments powered by Disqus
 
Email:
Retype Email:
Country
Zip Code:
 
Hot Topics
Follow Newsmax
Like us
on Facebook
Follow us
on Twitter
Add us
on Google Plus
Around the Web
You May Also Like

Blood Tests May Predict How Long Lou Gehrig's Patients Have to Live

Tuesday, 22 Jul 2014 12:30 PM

Simple blood tests may one day help predict survival and the course of the disease in people with amyotrophic lateral sc . . .

Parents of Autistic Children Need Help, Too

Tuesday, 22 Jul 2014 12:26 PM

Most therapies for autism focus on the child, but new research suggests the child's stressed-out parents could benefit f . . .

Improved Nicotine Patch Weans Users

Tuesday, 22 Jul 2014 12:22 PM

Conventional patches provide a steady supply of nicotine, but the electronic SmartStop proactively addresses situations  . . .

Most Commented

Newsmax, Moneynews, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, NewsmaxWorld, NewsmaxHealth, are trademarks of Newsmax Media, Inc.

 
NEWSMAX.COM
America's News Page
©  Newsmax Media, Inc.
All Rights Reserved